Christopher D.�M. Fletcher

Top papers

• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

  George D. Demetri, Margaret von Mehren, Charles D. Blanke, et al.·2002·New England Journal of Medicine
  ↗ 4,375OA
• Diagnosis of gastrointestinal stromal tumors: A consensus approach

  Christopher D.�M. Fletcher, Jules J. Berman, Christopher L. Corless, et al.·2002·Human Pathology
  ↗ 3,448
• WHO classification of tumours of soft tissue and bone

  Christopher D.�M. Fletcher·2013·IARC Press eBooks
  ↗ 2,873
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone

  Christopher D.�M. Fletcher, Krisjnan Unni, Fredrik Mertens·2002·Lund University Publications (Lund University)
  ↗ 2,810
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

  George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, et al.·2006·The Lancet
  ↗ 2,591
• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

  Michael C. Heinrich, Christopher L. Corless, George D. Demetri, et al.·2003·Journal of Clinical Oncology
  ↗ 2,291
• <i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors

  Michael C. Heinrich, Christopher L. Corless, Anette Duensing, et al.·2003·Science
  ↗ 2,288
• Pathology and genetics of tumours of soft tissue and bone

  Christopher D.�M. Fletcher, K. Krishnan Unni, Fredrik Mertens·2002·IARC Press eBooks
  ↗ 2,075
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

  Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla, et al.·2012·The Lancet
  ↗ 2,066OA
• Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

  Charles D. Blanke, Cathryn Rankin, George D. Demetri, et al.·2008·Journal of Clinical Oncology
  ↗ 1,075
• Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

  Charles D. Blanke, George D. Demetri, Margaret von Mehren, et al.·2008·Journal of Clinical Oncology
  ↗ 1,001OA
• Differentiation and reversal of malignant changes in colon cancer through PPARγ

  Pasha Sarraf, Elisabetta Mueller, Daniel M. Jones, et al.·1998·Nature Medicine
  ↗ 972